Cathay Health Increases its Stake in TISSIUM with €50M Series D
New financing to support TISSIUM’s commercial launch and platform extension
PARIS, May 23, 2023 — Today, Cathay Health announced its participation in the €50M Series D round of TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction. The investor syndicate brings new investors such as Fonds Stratégique des Transitions, managed by ISALT as well as Merieux Developpement, and includes historical investors such as Credit Mutuel Innovation and Sofinnova Partners.
Cathay Health reinvested over pro rata in this round of financing, based on the progress the company has made to get into clinical studies, its corporate development and its advancing commercial plans as well as its vision for further developing its product pipeline.
This latest funding round coincides with the achievement of important milestones for TISSIUM, notably its on-going first-in-human study on its first nerve repair product, COAPTIUM Connect, in Australia and the preparation of the commercialisation of its first products in nerve and hernia repair. The financing will allow TISSIUM to continue to execute on its development plan, funding the company for the commercialisation of its first products in nerve and hernia repair and fueling the extension of its pipeline of products and its platform.
TISSIUM will continue to pursue rapid international expansion, leveraging in-house production and state-of-the-art manufacturing facilities, as well as entering partnerships in certain verticals. In parallel, it will broaden its platform with more specialized products in the existing verticals (nerve, hernia and cardiovascular) while also extending to other verticals in new therapeutic areas.
“With the closing of our Series D financing round, TISSIUM is well-positioned to finance the commercialization of its first products. This funding significantly bolsters our ability to move with speed towards our goal of enhancing tissue reconstruction for patients. We look forward to continuing our work to bring innovation in the space and develop products that make a difference in patients’ lives.”
— Christophe Bancel, CEO of Tissium
“Since leading TISSIUM’s 2021 Series C, we’ve been continuously impressed with the team and the company’s strong progress in developing multiple clinical programs off the TISSIUM biopolymer technology platform. We continue to believe that TISSIUM is creating the future of tissue reconstruction and are proud to continue supporting the company’s clinical and commercial growth of its expandable platform that can be applied toward driving better outcomes in multiple, large therapeutic areas.”
— Hongjie Hu, Co-founder & Managing Partner at Cathay Health
TISSIUM, a privately-owned MedTech company based in Paris, France and Boston, USA, is dedicated to the development and commercialization of products derived from its unique biopolymer platform. The company’s products will address multiple unmet clinical needs, including atraumatic tissue repair and reconstruction.
TISSIUM is developing a portfolio of products that leverage its proprietary family of fully biosynthetic, biomorphic, and programmable polymers, which are the foundation of the company’s technology platform. Currently, the Company has a pipeline of seven products across three verticals, including sutureless nerve repair, hernia repair and cardiovascular sealants. Each product is designed to enhance the tissue reconstruction process in a unique way. In addition, the company develops complementary delivery and activation devices for enhanced performance and usability of its products.
TISSIUM’s technology is based on world-class research and intellectual property from the laboratories of Professor Robert Langer (MIT) and Professor Jeffrey M. Karp (Brigham and Women’s Hospital), who co-founded the company in 2013.
For more information, please visit: www.TISSIUM.com
Follow us on LinkedIn, Twitter @TISSIUMtech
About Cathay Health
Cathay Health, affiliated to Cathay Capital, is a global fund investing at the convergence of healthcare, life sciences and technology. As a multi-stage venture and growth fund, it backs convergence medicine companies across Europe, North America and Asia whose tech-enabled solutions catalyze groundbreaking advances in medicine. Its global platform brings together startups, established companies and large corporations to fuel cross-border, cross-industry collaboration and growth with direct access to new markets, partners and patients. From the world’s leading life sciences and technology hubs, including San Francisco, New York, London, Cambridge, Paris, Basel and Shanghai, Cathay Health partners with future leaders in the data-driven medicine era that will transform human health and care in all its dimensions.